CHI Releases List of Delegates for Targeting Cancer Stem Cells Symposium in San Francisco, CA

PRLog (Press Release) - Jan. 31, 2013 - The science of cancer stem cells is still evolving, and despite the many unknowns, holds significant promise for the next phase of oncology therapeutics.  Advances in understanding the origin of cancer stem cells, and their role in tumor development and metastasis are shedding new light on the challenge of treatment resistance and disease recurrence.  At CHI’s Targeting Cancer Stem Cell symposium, the following commercial and academic organizations will come together to discuss promising new therapeutics for oncology:

Alligator Bioscience AB
American Laboratory
Amgen Inc.
Barclays Capital
Bionomics Inc.
Boston Biomedical Inc.
Cedars Sinai Medical Center
Celera Corp.
Cellerant Therapeutics Inc.
CureMeta LLC
Daiichi Sankyo Co Ltd.
Dainippon Sumitomo Pharma Co Ltd.
Eli Lilly & Co.
EMD Serono
ETH Zurich
Evgen Ltd.
Fluidigm Corp.
Genentech Inc.
Illumina
IMEC
Janssen R&D LLC
John Wayne Cancer Institute
JSR Life Sciences Corp.
Kaiser Permanente
Latvian Biomedical Research & Study Center
MacroGenics Inc.
McMaster University
Miltenyi Biotec GmbH
Mount Sinai School of Medicine
Novartis Institutes for BioMedical Research
OncoMed Pharmaceuticals Inc.
Ono Pharma USA
Onyx Pharmaceuticals Inc.
Oregon Health & Science University
Osaka University
Panagene
Personal Genomics Institute
Pfizer Inc.
PLUS Diagnostics
Pontificia University Catolica de Chile
Quanticel Pharmaceuticals
Roche Molecular Systems Inc.
Sears Capital Management
Sillman Consulting
Southern Illinois University
SRI International
STMicroelectronics
Summit Pharmaceuticals Intl Corp.
TetraQ
UK Trade & Investment
University of Auckland
University of California Los Angeles
University of California Los Angeles
University of California San Diego
University of Michigan
University of Minnesota Twin Cities
University of Texas Dallas
University of Ulster
University of Virginia
University of Wisconsin Madison
Verastem Inc.
Vertex Pharmaceuticals Inc.

Full details on this symposium can be viewed at http://www.triconference.com/targeting-cancer-stem-cells

As part of the Molecular Med TRI-CON 2013, attendees have access to 5 symposia, 16 short courses, and 19 core programs around 5 scientific channels: diagnostics, therapeutics, clinical, informatics, and cancer. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.

To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi lscimemi@healthtech.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) (www.healthtech.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.

Contact:
James Prudhomme
Cambridge Healthtech Institute
(781) 972-5400
jprudhomme@healthtech.com